Premium
Video‐urodynamic effects of mirabegron, a β 3 ‐adrenoceptor agonist, in patients with low‐compliance bladder
Author(s) -
Kamei Jun,
Furuta Akira,
Akiyama Yoshiyuki,
Niimi Aya,
Ichihara Koji,
Fujimura Tetsuya,
Fukuhara Hiroshi,
Kume Haruki,
Homma Yukio,
Igawa Yasuhiko
Publication year - 2015
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12867
Subject(s) - mirabegron , medicine , agonist , urology , compliance (psychology) , urinary bladder , overactive bladder , receptor , pathology , psychology , social psychology , alternative medicine
Objectives To investigate video‐urodynamic effects of mirabegron, a β 3 ‐adrenoceptor agonist, on low‐compliance bladder. Methods We retrospectively reviewed nine patients (three men, six women, age 17–68 years) who had been diagnosed with lower urinary tract dysfunction with low‐compliance bladder, and who underwent video‐urodynamic study before and during administration of mirabegron 50 mg once daily. Urodynamic parameters were compared before and after treatment. Results Mirabegron treatment significantly increased first desire to void and cystometric capacity with an average increment of 80 mL ( P = 0.027) and 123 mL ( P = 0.005), respectively. Bladder compliance also significantly increased (mean value 8.1 mL/cmH 2 O before, 18.2 mL/cmH 2 O after, P = 0.024). In the six patients who had been taking anticholinergic agents at baseline video‐urodynamic study and then switched to mirabegron, mean cystometric capacity and bladder compliance were also increased significantly from 208.3 to 346.8 mL ( P = 0.015) and from 7.2 to 17.5 mL/cmH 2 O ( P = 0.047), respectively. Vesicoureteral reflux grade was improved in three of the four patients who had shown vesicoureteral reflux on cystography before treatment. Conclusions Mirabegron improves cystometric capacity and bladder compliance, and it lowers vesicoureteral reflux grade in patients with low‐compliance bladder. Thus, mirabegron might represent a good alternative drug for low‐compliance bladder refractory to anticholinergic treatment.